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The work presented in this thesis was aimed at charactenzing cationic liposome-
mediated transfection and, more specifically, investigated the properties of the
synthetic cationic lipid SAINT-2. In this final chapter, the data obtained with SAINT-
2 containing liposomes will be summarized and discussed. Some perspectives
concerning the future application of cationic liposomes in different gene therapy
approaches will also be presented.
Over the last 10-15 years, considerable progress was made in the development of
competent DNA delivery systems. This has paralleled the course of preclinical and
clinical studies employing gene therapy, setting increasingly higher requirements in
terms of safety and efficiency of the vectors. In particular, the development of
cationic liposomes for such a purpose has generated extensive work and these
systems may well play an indispensable role in gene therapy. The structure and
physico-chemical properties of these complexes with DNA (lipoplexes) have been
elucidated, as well as the (intra-)cellular events leading to transgene expression irr
vitro. The potential of lipoplexes for therapeutic purposes has been tested in diverse
animal models and is currently under clinical investigations. As an introduction,
Chapter 1 situates cationic liposon"res in the general context of gene therapy and
presents progresses in research on lipoplexes in vivo. In chapter 2, various
parameters, such as lipid:DNA ratio, size of the lipoplexes or the effect of serum,
influencing lipofection in vítro and in vivo, are reviewed. Recent improvements in
lipoplex technology regarding efficiency, stabilization and targeting are also
described.
The main objective of the work presented in this thesis was to improve our
understanding of the parameters that modulate SAlNT-mediated transfection. Also,
the potential of SAINT-2 cationic liposomes as gene carriers for gene therapy
applications was tested. In chapters 3 and 4,we studied several aspects of transfection
in vitro, employing different cell l ines. The transfection efficiency of numerous
cationic lipid-based formulations is impaired by the presence of serum. Therefore, the
influence of this factor on SAINT lipoplexes was investigated (chapter 3). It was
established that transgene xpression levels obtained in several cell l ines with SAINT
lipoplexes, in contrast to Lipofectin, were not heavily affected by the presence of
semm. The behavior in serum was not only dependent on the nature of the cationic
lipid but also on the helper lipid iqcluded in the liposomes, and interestingly on the
cell l ine tested. Transfection-related cytotoxicity was reduced when serum was
present. At the lipoplex level, we observed a direct stabilizing effect of serurn,
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particles over time. Altogether, the data showed that serum affected the transfection
process at different stages during lipoplex-cell interaction. The insensitivity of SAINT
transfection toward the presence of serum is an interesting finding, but extrapolation
to an in vivo situation should be considered with much care. The stability of
lipoplexes in mouse serum has been related to in vivo transfection efficiency. SAINT
lipoplexes were stabilized in l0oÁ serum but this does not exclude destabilization at
higher serum concentrations.
In order to develop a 'stealth' SAINT formulation, a small percentage of
poly(ethylene glycol)-modified lipids was introduced in SAINT lipoplexes, and the
effect of this modification was examined in an in vitro system (chapter 4). The PEG
technology was initially developed to prolong the circulation time of classical
liposomes after i.v. administration and is based on the hydrophilicity of the PEG
groups, masking the particle. It was speculated that, similarly, a PEG-coating could
stabilize lipoplexes and at the same time reduce its non-specific interactions with
cells/ blood components. This hypothesis was tested with four species of PEGylated
lipids that differed by the length of their acyl chain. This variation modulates
anchoring properties in a lipid bilayer, short-chain PEG-lipids exchanging more
rapidly than long-chain ones in the presence of an acceptor membrane. Addition of
PEG-lipids did not compromise lipoplex formation but reduced the average size of
the lipoplexes. An important finding was that transfection properties of SAINT
liposomes in B16-Fl0 cells were dramatically affected by the introduction of PEG-
lipids. When the PEG-lipids were included in the liposomes, transfection with the
resulting PEG-lipoplexes was totally inhibited for the long chain PEG-lipids and to a
large extent for the short-chain ones. By adding the PEG-lipids concomitantly to
lipoplex formation, we observed no inhibition of transfection with the long chain
PEG-species whereas the inhibition obtained with the short-chain species was not
significantly different. PEG-lipoplexes were quickly taken up in the cells, using either
method of lipoplex PEGylation, suggesting a different intracellular pathway for
PEGylated vs. non-PEGylated lipoplex, i.e. one leading to degradation and the other
allowing escape of the DNA before degradation. The net positive charge of the PEG-
lipoplexes was identified as the parameter determining cell-lipoplex interaction, as the
binding of PEG-lipoplexes could be reduced by lowering the (+/-) ratio from 4:1 to
2:1. Taken together, these data revealed a profound influence of PEG-lipids on the
lipoplexes and on the transfection process. Interestingly, the cellular binding of the
PEG-lipoplexes was modulated by the net charge ratio of the lipoplexes and could
only be inhibited when decreasing this ratio.
The studies presented in chapters 5 and 6 investigated the ability of SAINT lipoplexes
to transfect a tumor in vivo. To this end, a murine melanoma model presenting a
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subcutaneous tumor was used, and the lipoplexes were applied by local and systemic
administration. Following intravenous injection (chapter 5), firstly safety of the
SAINT lipoplex treatment was evaluated. At the concentrations required for in vivo
injection, lipoplexes prepared in 0.9 % NaCl rapidly precipitated in vitro and were
found to induce mild toxicity in healthy BALB/c mice in vivo. Apathy, fur ruffling,
leukopenia (drop in the number of circulating white blood cells: WBC) and
hypertrophy of the spleen were evidenced at a dose of I pg DNA (combined with 15
nmol SAINT liposomes), but these symptoms resolved within a few days. Preparing
the lipoplexes rn 50Á glucose resulted in an improved stability (no precipitation iru
vitro) and drastically decreased the toxicity of SAINT lipoplexes. Mice received
lipoplexes containing 5 prg and 25 pg DNA without notable changes in the WBC
counts and without apparent liver pathology. Still, the red pulp in the spleen of all
animals was slightly increased, and mice injected with 25 pg DNA displayed
transient fur ruffling. We then studied the biodistribution of SAINT lipoplexes in
mice bearing a subcutaneous tumor, and how this was influenced by PEGylation of
the lipoplexes. One important question was whether the PEG-lipids could prolong the
circulation time of SAINT lipoplexes and thereby enhance their uptake into the tumor
or not. Following radiolabeled lipoplexes after i.v. injection, a rapid blood
disappearance of SAINT lipoplexes was observed, il lustrating a general feature of this
class of delivery agents. After 10 min, no radioactivity was detected in the blood for
non-PEGylated lipoplexes or lipoplexes containing 5% PEG-lipid. However, the
radioactivity still present in the blood after the same time was slightly increased for
lipoplexes containing 10% PEG-PE compared to non-PEGylated lipoplexes. Organ
distribution studies revealed that SAINT lipoplexes, with or without PEG-Iipids, were
taken up in the liver and spleen within 10 minutes, contrasting with many
formulations which usually display an intermediary step of lung accumulation. This
finding may be explained by u rapid destabilization of the lipoplexes, which could
depend on (i) the lipoplex formulation, including DOPE as helper lipid, and (ii) a
relatively low net positive charge (with a +l- ratio of 2:l ). The amount of radioactivity
detected in the tumor was negligible and optimrzatron apparently is needed to adapt
SAINT lipoplexes to tumor delivery by systemic administration. This should include
approaches to prolong the circulation time of the particles by reducing non-specific
interactions and uptake by macrophages. PEG-lipids bearing a longer hydrophilic
chain (PEG5e6e) than the ones used in our experiments n-ray be useful for this purpose.
Indeed, our data (chapters 4 & 5) suggest that the electrostatic interactions between
lipoplexes and cells (in combination with blood components) are difficult to block by
incorporation of PE,G2eee-lipids. The failure to detect expression of the transgene in
lung, liver and spleen could indicate that the detection method used was not sensitive










































































enough, or that the lipoplex was destabilized leading to DNA degradation. The
locahzation of the lipoplexes in liver and spleen without expression of the transgene
suggests that the absence of expression in these organs was due to uptake by
macrophages. Accumulation in the liver could be turned as an advantage to apply
treatment to this organ, but the lipoplexes should then be targeted to hepatocytes in
order to obtain transgene xpression. The nature of the helper lipid is a key factor for
the behavior of systemically applied lipoplexes and replacing DOPE by cholesterol in
our system may enhance the circulation time of SAINT lipoplexes, thus modifying
their biodistribution and possibly leading to a better transgene xpression.
Local administration limits the number of barriers to overcome before reaching the
cells of interest. The possibility to use SAINT lipoplexes for local treatment was
tested in a mouse melanoma model. The results, presented in chapter 6,
unambiguously demonstrate the expression of two different reporter genes following
intratumoral injection of 5 pg DNA complexed with SAINT liposomes at a ratio of
15:1 nmollptg.The use of the GFP gene in combination with fluorescently labeled
liposomes revealed that diffusion through the tumor of both components had
occuned. Whether this observation relies on the tumor model itself or on the SAINT
lipoplex is stil l unclear. Comparable studies in other tumor models should clarify this
point. Quantification of expression levels by the luciferase assay showed an increased
transfection ability of SAINT lipoplexes compared to naked DNA. In an attempt to
further enhance the efficiency of SAINT lipoplexes, the effect of ultrasound was
investigated. No influence on the level of transgene expression was found in our
model. The level of expression may be enhanced by modulation of parameters uch as
lipid:DNA ratio or DNA dose. Nevertheless, the demonstration of protein expression
after intratumoral injection of SAINT lipoplexes suggests that a therapy may be
successfully applied in this model by administration of SAINT lipoplexes containing
a therapeutic gene.
Perspectives
The results obtained with SAINT lipoplexes that are presented in this thesis
demonstrate he potential of the SAINT-2 amphiphile in therapeutic gene delivery
approaches. However, our data also reflect limitations associated with cationic lipid-
based systems and raise several points about their future development and
applications in gene therapy. Among the vectors available, non-viral systems remain
attractive compared to viral ones, notably because of ease and low cost of production,
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the convenience of use, the relative safety of administration with the possibility to
repeat injection.
For the time being, realistic indications for cationic lipid-based devices are limited to
local administration. Preclinical studies have validated the use of cationic
liposome/DNA complexes for treatment of cystic fibrosis and certain tumors, but
such successes have been translated in the clinic only to a limited extent. The
demonstration of transgene expression in patients, following pulmonary or tumoral
administration of lipoplexes, is an encouraging start. The proteins expressed appeared
functionally active, which indicates that the lack of therapeutic benefit could be due
to the insufficient level of expression. Several phase II trials are still ongoing and
their outcome will provide complementary information to evaluate cationic liposomes
for clinical application. Other gene therapy applications that could make use of
cationic liposomes are vaccination, treatment of hemophilia B and cardiovascular
diseases. In these cases, local transgene expression is required in the skin, muscle or
vascular wall and these tissues are efficiently transfected by lipoplexes as
demonstrated by in vivo studies. Intravenous injection represents a further step, and
may be proposed for lung diseases, due to the intrinsic lung targeting property of
lipoplexes.
Improvement of efficiency and targeting of transfection remain major challenges in
the field of non-viral vectors. These are 'sine qua non' conditions for successful
application in systemic gene therapy. Next to vector engineering, modifications at the
DNA level may prove valuable to reach these goals. For instance, strong non-viral
promoters, less susceptible to inactivation by inflammatory cytokines, may prolong
the duration of expression and the use of tissue specific promoters is an interesting
approach for targeting purposes. Unmethylated sequences on bacterial DNA induce
inflammatory responses after lipoplex administration, leading to transgene
inactivation. Eukaryotic DNA or DNA methylation could limit the activation of the
innate immune system and thereby enhance duration of transgene expression.
Parameters such as lipid:DNA ratio and helper lipid, that affect the physical
properties of the lipoplexes and their in vivo distribution and efficiency, should be
carefully optimized for each cationic lipid and therapeutic indication. The vector
should combine condensing, protecting, stabilizing and targeting properties, with
retention of transfection activity. It is thus not excluded that cationic liposomes
reahze fully their potential in combination with polycations or peptides confering
additive properties to the system. Polycations can improve stability and efficiency of
the lipoplexes and a targeting moiety can be easily attached to their structure.
Custom-made peptides including DNA binding, tissue targeting and nuclear







































of efficient and specific vectors. Targeting of the lipoplexes may also involve
attachment of antibodies (or fragments) and ligands to the vector, a technology
previously developed for conventional iposomes. The notion of targeting actually
includes several aspects. In the case of local administration, targeting may also
increase cellular uptake and thus transfection efficiency. After systemic delivery, the
aim of targeting can be to selectively increase the accumulation in a specific organ.
Research in the field of drug delivery has identified many potential targets and this
knowledge could prove highly valuable for gene transfer. As an example, the RGD
motif recognizing integrins expressed on the tumor vasculature may be coupled to
lipoplexes to target tumors. Targeting may be used to allow crossing of endothelial
barriers. For instance, antibody targeting to the transferrin receptor allows
transcytosis across the blood brain barrier of liposomes and proteins. Antibody
targeting of a lung specific caveolae component can target proteins to the lung
through the lung endothelium. We can predict that more organ-specific, endocytotic
or transcytotic targets will be identified in the coming years, allowing specific
addressing of drug and possibiy lipoplexes and passage across endothelial and
epithelial barriers.
Finally, it should be kept in mind that a universal vector to serve multiple purposes
may not be a realistic option and that each vector may be the answer to a particular
indication.
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